MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-11-2023
ViewRay Cost of Revenue 2011-2026 | VRAY
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue ViewRay
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 92.2 M | 69.8 M | 61.1 M | 93.3 M | 74.4 M | 27.7 M | 25.9 M | 14.5 M | 9.15 M | 8.19 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 93.3 M | 8.19 M | 47.6 M |
Quarterly Cost of Revenue ViewRay
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 M | - | - | - | 18.8 M | - | 17.3 M | 16.7 M | 15.2 M | - | 11.2 M | 15.3 M | 16.4 M | - | 20.3 M | 26.9 M | 25.6 M | - | 17.3 M | 16.4 M | 20.6 M | - | 10.2 M | 826 K | 1.04 M | - | 1.18 M | 863 K | 6.53 M | - | 6.09 M | 833 K | 777 K | - | 2.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 26.9 M | 777 K | 12.2 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
1.2 B | $ 185.02 | -0.81 % | $ 13.9 B |  USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 12.58 | -0.55 % | $ 1.7 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 38.94 | -1.37 % | $ 5.8 K | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.59 | 1.99 % | $ 134 M |  France |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 63.42 | -1.83 % | $ 93.9 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.61 | 3.18 % | $ 38 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 10.5 | 0.38 % | $ 297 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
14 M | $ 25.39 | -1.24 % | $ 215 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Globus Medical
GMED
|
958 M | $ 92.76 | -1.87 % | $ 12.5 B | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.06 | 6.19 % | $ 1.25 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 5.29 | 8.74 % | $ 1.12 B | USA |
 |
Inogen
INGN
|
194 M | $ 6.59 | 6.29 % | $ 175 M | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.04 | - | $ 17.6 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 16.53 | -7.39 % | $ 388 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 10.83 | -1.46 % | $ 388 M | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 56.45 | -0.34 % | $ 1.66 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 37.91 | -3.88 % | $ 1.18 B | USA |
 |
LENSAR
LNSR
|
31.3 M | $ 5.8 | -7.2 % | $ 69.4 M | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 65.01 | -0.2 % | $ 3.55 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 88.37 | 0.49 % | $ 3.07 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 79.05 | 1.09 % | $ 46.2 B | USA |
 |
Penumbra
PEN
|
461 M | $ 331.47 | -0.29 % | $ 12.9 B | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |